Home / Stocks / ABBV

AbbVie (ABBV, Biotechnology) Stock Valuation & Fair Value Significantly overvalued

AbbVie (ABBV, Biotechnology) trades at a blended P/E of 20.2, about 46% above its historical normal valuation, with a forward growth estimate of 15.2% and a PEG of 1.33. Analysts' one-year estimates have been hit 73% of the time. Priced at its historical normal P/E of 13.9 on the same blended earnings, the 2026-10-02 close of $262.82 corresponds to about $181 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-10-05
Blended P/E
20.2
Normal P/E
13.9
PEG
1.33
Fwd growth
15.2%
Div yield
2.6%
RSI (14)
67.1
Neutral
Technical context
  • Price $272.42 at the 2026-10-08 close, 3.1% above the 20-day average ($264.34) and 5.4% above the 50-day ($258.51).
  • RSI (14) at 67.1.
  • 52-week range $195.99 to $272.42: the price is at the high and 39.0% above the low.

The Street vs SeerForecast

Wall Street's mean price target for ABBV is $278.86 across 28 analysts, 2.4% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from favorable on our tests (2026-06-03) to significantly overvalued (2026-10-05).

Blended P/E and rating by weekBlended P/E moved from 18.6 to 20.2 between 2026-06-03 and 2026-10-02, against a normal P/E of 13.9, with 3 rating changes over 37 recorded weeks.2026-06-03: P/E 18.6, Favorable on our tests, recalculated for the week of 2026-06-032026-06-10: P/E 19.2, Favorable on our tests, recalculated for the week of 2026-06-102026-06-12: P/E 19.2, Favorable on our tests, recalculated for the week of 2026-06-142026-06-16: P/E 19.2, Favorable on our tests, recalculated for the week of 2026-06-162026-06-18: P/E 19.2, Favorable on our tests, recalculated for the week of 2026-06-212026-07-02: P/E 20.7, Significantly overvalued, recalculated for the week of 2026-07-022026-07-06: P/E 21.5, Significantly overvalued, recalculated for the week of 2026-07-062026-07-09: P/E 21.5, Significantly overvalued, recalculated for the week of 2026-07-092026-07-10: P/E 20.4, Favorable on our tests, recalculated for the week of 2026-07-122026-07-13: P/E 20.4, Favorable on our tests, recalculated for the week of 2026-07-132026-07-14: P/E 20.4, Favorable on our tests, recalculated for the week of 2026-07-142026-07-20: P/E 20.9, Favorable on our tests, recalculated for the week of 2026-07-202026-07-22: P/E 20.9, Favorable on our tests, recalculated for the week of 2026-07-222026-07-24: P/E 21.1, Favorable on our tests, recalculated for the week of 2026-07-252026-07-27: P/E 21.1, Favorable on our tests, recalculated for the week of 2026-07-272026-07-31: P/E 20.8, Favorable on our tests, recalculated for the week of 2026-07-312026-07-31: P/E 20.4, Favorable on our tests, recorded live 2026-08-032026-08-07: P/E 19.7, Favorable on our tests, recalculated for the week of 2026-08-072026-08-07: P/E 19.8, Favorable on our tests, recorded live 2026-08-102026-08-14: P/E 20.1, Favorable on our tests, recalculated for the week of 2026-08-142026-08-14: P/E 20.0, Favorable on our tests, recorded live 2026-08-172026-08-21: P/E 20.9, Significantly overvalued, recalculated for the week of 2026-08-212026-08-21: P/E 21.1, Significantly overvalued, recorded live 2026-08-242026-08-27: P/E 21.1, Significantly overvalued, recalculated for the week of 2026-08-272026-08-28: P/E 20.5, Significantly overvalued, recalculated for the week of 2026-08-282026-08-28: P/E 20.2, Significantly overvalued, recalculated for the week of 2026-08-302026-08-28: P/E 20.2, Significantly overvalued, recorded live 2026-08-312026-09-04: P/E 20.2, Significantly overvalued, recalculated for the week of 2026-09-052026-09-04: P/E 20.2, Significantly overvalued, recorded live 2026-09-072026-09-11: P/E 20.1, Significantly overvalued, recalculated for the week of 2026-09-122026-09-11: P/E 20.1, Significantly overvalued, recorded live 2026-09-142026-09-18: P/E 20.5, Significantly overvalued, recalculated for the week of 2026-09-192026-09-18: P/E 20.5, Significantly overvalued, recorded live 2026-09-212026-09-25: P/E 20.4, Significantly overvalued, recalculated for the week of 2026-09-262026-09-25: P/E 20.4, Significantly overvalued, recorded live 2026-09-282026-10-02: P/E 20.2, Significantly overvalued, recalculated for the week of 2026-10-032026-10-02: P/E 20.2, Significantly overvalued, recorded live 2026-10-0514.016.018.020.0Jun 3Jul 3Aug 2Sep 2Oct 2Normal P/E 13.9
Favorable on our testsSignificantly overvaluedLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 18.6+34%Favorable on our tests (recalculated)
2026-07-02P/E 20.7+49%Significantly overvalued (recalculated)
2026-07-06P/E 21.5+55%Significantly overvalued (recalculated)
2026-07-12P/E 20.4+47%Favorable on our tests (recalculated)
2026-08-21P/E 20.9+50%Significantly overvalued (recalculated)
2026-10-05P/E 20.2+46%Significantly overvalued ← now
Show all 37 weeks
WeekBlended P/EPremium to normal P/ERating
2026-06-03P/E 18.6+34%Favorable on our tests (recalculated)
2026-06-10P/E 19.2+38%Favorable on our tests (recalculated)
2026-06-14P/E 19.2+38%Favorable on our tests (recalculated)
2026-06-16P/E 19.2+38%Favorable on our tests (recalculated)
2026-06-21P/E 19.2+38%Favorable on our tests (recalculated)
2026-07-02P/E 20.7+49%Significantly overvalued (recalculated)
2026-07-06P/E 21.5+55%Significantly overvalued (recalculated)
2026-07-09P/E 21.5+55%Significantly overvalued (recalculated)
2026-07-12P/E 20.4+47%Favorable on our tests (recalculated)
2026-07-13P/E 20.4+47%Favorable on our tests (recalculated)
2026-07-14P/E 20.4+47%Favorable on our tests (recalculated)
2026-07-20P/E 20.9+50%Favorable on our tests (recalculated)
2026-07-22P/E 20.9+50%Favorable on our tests (recalculated)
2026-07-25P/E 21.1+52%Favorable on our tests (recalculated)
2026-07-27P/E 21.1+52%Favorable on our tests (recalculated)
2026-07-31P/E 20.8+50%Favorable on our tests (recalculated)
2026-08-03P/E 20.4+47%Favorable on our tests
2026-08-07P/E 19.7+42%Favorable on our tests (recalculated)
2026-08-10P/E 19.8+43%Favorable on our tests
2026-08-14P/E 20.1+45%Favorable on our tests (recalculated)
2026-08-17P/E 20.0+44%Favorable on our tests
2026-08-21P/E 20.9+50%Significantly overvalued (recalculated)
2026-08-24P/E 21.1+52%Significantly overvalued
2026-08-27P/E 21.1+52%Significantly overvalued (recalculated)
2026-08-28P/E 20.5+47%Significantly overvalued (recalculated)
2026-08-30P/E 20.2+46%Significantly overvalued (recalculated)
2026-08-31P/E 20.2+46%Significantly overvalued
2026-09-05P/E 20.2+45%Significantly overvalued (recalculated)
2026-09-07P/E 20.2+45%Significantly overvalued
2026-09-12P/E 20.1+45%Significantly overvalued (recalculated)
2026-09-14P/E 20.1+45%Significantly overvalued
2026-09-19P/E 20.5+48%Significantly overvalued (recalculated)
2026-09-21P/E 20.5+48%Significantly overvalued
2026-09-26P/E 20.4+47%Significantly overvalued (recalculated)
2026-09-28P/E 20.4+47%Significantly overvalued
2026-10-03P/E 20.2+46%Significantly overvalued (recalculated)
2026-10-05P/E 20.2+46%Significantly overvalued ← now

Frequently asked questions

Is AbbVie stock overvalued?

At a blended P/E of 20.2 versus its historical normal P/E of 13.9, AbbVie trades about 46% above its typical valuation, with a PEG of 1.33 on 15.2% forward growth. tickerseer currently rates it significantly overvalued.

What is AbbVie's fair value and PEG?

AbbVie trades at a blended P/E of 20.2 against a historical normal P/E of 13.9, a PEG of 1.33, and a forward growth estimate of 15.2%. Priced at its historical normal P/E of 13.9 on the same blended earnings, the 2026-10-02 close of $262.82 corresponds to about $181 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of AbbVie changed?

tickerseer's rating moved from favorable on our tests (2026-06-03) to significantly overvalued (2026-10-05).

What is the analyst price target for AbbVie?

The mean Wall Street price target for AbbVie is $278.86 across 28 analysts, 2.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ABBV free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.